Journal
LANCET
Volume 358, Issue 9299, Pages 2127-2128Publisher
LANCET LTD
DOI: 10.1016/S0140-6736(01)07184-7
Keywords
-
Categories
Ask authors/readers for more resources
Asymmetrical dimethylarginine (ADMA) is an endogenous nitric oxide synthase Inhibitor, which has been suggested to be a novel independent risk factor for endothelial dysfunction and coronary heart disease. We investigated the association of ADMA concentration In serum with risk of acute coronary events. We did a prospective, nested, case-control study in middle-aged men from eastern Finland. In an analysis of men who did not smoke, those who were in the highest quartile for ADMA (>0.62 mu mol/L) had a 3.9-fold (95% CI 1.25-12.3, p=0.02) increase in risk of acute coronary events compared with the other quartiles. Our findings suggest that ADMA is a predictor of acute coronary events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available